Trial Profile
Glucagon-like Peptide-1 Receptor Agonists as Novel Pharmacotherapies for Nicotine Dependence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms DAL
- 26 May 2022 Status changed from active, no longer recruiting to completed.
- 20 Dec 2021 Planned End Date changed from 1 Jul 2022 to 15 Aug 2022.
- 20 Dec 2021 Planned primary completion date changed from 1 Jul 2022 to 18 Jul 2022.